EICHORPublic-registry site landscape for NCT07751744, “Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma”, a Brain Metastases From Solid Tumors study sponsored by Jubilant Therapeutics Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07751744 (registry record) |
| Study title | Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma |
| Official title | A Phase 1/2, Multicenter, Open-Label, Dose-Escalation/Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered JBI-778 in Patients With Brain Metastasis, Leptomeningeal Disease, or High Grade Recurrent Glioma |
| Sponsor | Jubilant Therapeutics Inc. |
| Condition(s) | Brain Metastases From Solid Tumors; Leptomeningeal Disease; High Grade Glioma (HGG); Glioblastoma (GBM) |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 0 |
| Intervention(s) | JBI-778 |
Patient-friendly overview of this study: eichor.com/study/NCT07751744.
Eichor generates a preliminary site-risk snapshot for NCT07751744 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
